NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Intellia Therapeutics, Inc. to Contact the Firm Today!
Portfolio Pulse from
Bronstein, Gewirtz and Grossman, LLC has filed a class action lawsuit against Intellia Therapeutics (NTLA) alleging the company made false or misleading statements about its drug NTLA-3001's development and viability between July 30, 2024 and January 8, 2025. The lawsuit claims Intellia misrepresented the potential of viral-based editing programs and the drug's research and development capabilities.
April 10, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Class action lawsuit alleges false statements about drug development, which could negatively impact investor confidence and stock performance
The lawsuit directly targets Intellia Therapeutics, challenging the company's statements about its drug development program. This could lead to potential financial penalties, reputational damage, and decreased investor trust.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100